Skip to main navigation
Pharvaris N.V. Logo
  • Careers
  • Investors & Media
  • Contact
  • SCIENCE
  • PIPELINE
  • DISEASE FOCUS
  • HAE COMMUNITY
  • CLINICAL TRIALS
  • ABOUT US

Event Details

Investor Menu

IR Nav

  • Overview
  • News & Events
    News Releases Events Publications
  • Financials
    SEC Filings Quarterly Results
  • Stock
    Stock Performance Analyst Coverage
  • Corporate Governance
    Governance Documents Leadership Board of Directors Committee Composition
  • Resources
    Investor FAQs Contact Us Email Alerts

HAEi Regional Conference EMEA

Sep 1 - Sep 3, 2023

Supporting Materials

Early symptom relief following treatment with the oral bradykinin 2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks 1 MB
Efficacy and safety of bradykinin B2 receptor antagonism with oral deucrictibant in prophylaxis of hereditary 319.2 KB
Efficacy and safety of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in treatment of hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial 1 MB
Pharvaris N.V. Logo

CONTACT US

FOLLOW US

linkedin logo Facebook icon

©2026 Pharvaris N.V. © All Rights Reserved

  • Privacy Policy
  • Clinical Trial Privacy Notice
  • Global Privacy Laws
  • Terms of Use